Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK14 | Q16539 | 3/20 | 0.63 |
| ▸ | MLYCD | O95822 | 5/20 | 0.57 |
| ▸ | MPL | P40238 | 3/20 | 0.47 |
| ▸ | MAPK9 | P45984 | 2/20 | 0.45 |
| ▸ | MAPK10 | P53779 | 2/20 | 0.45 |
| ▸ | MAPK11 | Q15759 | 1/20 | 0.45 |
| ▸ | TDO2 | P48775 | 3/20 | 0.44 |
| ▸ | S1PR1 | P21453 | 2/20 | 0.41 |
| ▸ | CSNK1D | P48730 | 1/20 | 0.40 |
| ▸ | S1PR3 | Q99500 | 1/20 | 0.39 |
| ▸ | RPS6KB1 | P23443 | 1/20 | 0.38 |
| ▸ | AKT1 | P31749 | 1/20 | 0.38 |
| ▸ | AKT2 | P31751 | 1/20 | 0.38 |
| ▸ | AKT3 | Q9Y243 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4342443 | 0.85 | MAPK14 (0.71) | MAPK14MLYCDMAPK9MAPK10MAPK11 | |
| SCHEMBL4334530 | 0.82 | MAPK14 (0.66) | MAPK14MLYCDMAPK9MAPK10MAPK11 | |
| SCHEMBL4337126 | 0.82 | MAPK14 (0.66) | MAPK14MLYCDMAPK9MAPK10MAPK11 | |
| SCHEMBL4329365 | 0.82 | MAPK14 (0.66) | MAPK14MLYCDMAPK9MAPK10MAPK11 | |
| SCHEMBL27765848 | 0.80 | MAPK14 (0.63) | MAPK14MLYCDMAPK9MAPK10MAPK11 | |
| SCHEMBL4340388 | 0.79 | MAPK14 (0.66) | MAPK14MLYCDMAPK9MAPK10MAPK11 | |
| SCHEMBL4329246 | 0.79 | MAPK14 (0.66) | MAPK14MLYCDMAPK9MAPK10MAPK11 | |
| SCHEMBL4335625 | 0.79 | MAPK14 (0.61) | MAPK14MLYCDMAPK9MAPK10MAPK11 | |
| SCHEMBL4335181 | 0.79 | MLYCD (0.56) | MAPK14MLYCDMPLMAPK9MAPK10 | |
| SCHEMBL4334590 | 0.78 | MAPK14 (0.68) | MAPK14MLYCDMAPK9MAPK10MAPK11 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8207203-B2 | Pyridylisoxazole derivatives | ASKA PHARMACEUTICAL CO., LTD. (JP) | 2012-06-26 | — | — | US | disclosed |
| US-20090306145-A1 | Pyridylisoxazole Derivatives | ASKA PHARMACEUTICAL CO., LTD. (JP) | 2009-12-10 | — | — | US | disclosed |
| EP-2036905-A1 | PYRIDYLISOXAZOLE DERIVATIVE | ASKA Pharmaceutical Co., Ltd. (JP) | 2009-03-18 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090306145-A1 | Pyridylisoxazole Derivatives | CNKSR1, MAPK1, MAPK3 | MAPK14 43/4885MLYCD 4475/4885MPL 2313/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.